Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
Comment by Dumbeldorfwhiteon Sep 01, 2024 1:30pm

RE:RE:Theralase cash burn latest private placement

Which again is a bad look. Imagine particpating in the 1st tranche only to see them drop the price 2 more cents for the 2nd tranche. This team hasn't shown the ability to raise any cash.
88
Discussion
Comment by Dumbeldorfwhiteon Sep 01, 2024 1:28pm

RE:RE:RE:RE:RE:RE:RE:It’s allllllll talk

It's fine we ll just hear more excuses about slow enrollment due to the pandemic which has been over for 2 years. They won't even hit 90 I bet by the end of the year.
78
Discussion
Comment by Dumbeldorfwhiteon Sep 01, 2024 1:27pm

RE:RE:RE:It’s allllllll talk

Heavily invested him and his wife are making 650k a year! 
73
Discussion
Post by Dumbeldorfwhiteon Sep 01, 2024 1:23pm

Husband wife combo making 650k plus

Hahaha I mean what incentive is there to partner and possibly lose control? When u can sit back and make 650k plus options every year
562
Discussion
Comment by DeathXray33on Sep 01, 2024 11:38am

RE:AI friend Buster identifies these potential Dance Partners

"Founded in1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader ...more  
153
Discussion
Comment by Kayz88on Sep 01, 2024 11:29am

RE:RE:RE:RE:RE:RE:In closing...

Based on the earnings call and what RDW stated as their competitors. By all measures, TLT definitely has a higher duration % rate than the competitors. Here are the results. & ...more  
175
Discussion
Post by Alamir1111on Sep 01, 2024 11:18am

Shoe string

As an investor hearing from cs rdw that this co.achieved so many thing?on shoe string budget relying on cheap pp' i feel dissapointed as an investor or investors not doing enough to speed up ...more  
619
Comment by menoalittleon Sep 01, 2024 10:33am

RE:RE:AI friend Buster identifies these potential Dance Partners

No thank you to Roche. I hate ADR's (which is how Roche stock is predominately traded in the US) and it has a significantly lower dividend yield than MRK...
105
Discussion
Comment by Kayz88on Sep 01, 2024 10:28am

RE:RE:RE:RE:RE:In closing...

Here's the transcript: https://seekingalpha.com/article/4716277-theralase-technologies-inc-tltff-q2-2024-earnings-call-transcript?mailingid=36482698&messageid=2800&serial=36482698.27& ...more  
129
Discussion
Comment by CancerSlayeron Sep 01, 2024 9:50am

RE:RE:RE:RE:RE:It’s allllllll talk

From an investor's standpoint, both our partnership/financing options will certainly depend on the amount of this latest raise/tranche.   We shouldn't need a jv to reach BTD. Such a ...more  
183
Discussion
Comment by DeathXray33on Sep 01, 2024 9:20am

RE:AI friend Buster identifies these potential Dance Partners

I like ROCHE. ------------------------------------------------------------ August 21, 2024: "Rutherrin has been proven preclinically to be activated by Metformin, a common diabetes drug, without ...more  
158
Discussion
Comment by Alamir1111on Sep 01, 2024 9:19am

RE:RE:RE:RE:RE:RE:It’s allllllll talk

28 more patients to be treated to get to 100 by end of year
71
Discussion
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250